NASDAQ:PTIX
Protagenic Therapeutics, Inc. Common Stock Company Profile
$1.35
+0.0552 (+4.28%)
At Close: May 10, 2024
Information
149 Fifth Avenue, Suite 500
New York NY 10010
212 994 8200
www.protagenic.com
Industry: Biotechnology
Sector: Healthcare
Description
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
